New York, USA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iron Deficiency Anemia Market Size and Share to Grow by 2032, Predicts DelveInsight | Leading Companies Developing Therapies - Pharmacosmos, AMAG, Shield, Akebia, Keros, Keryx Biopharmaceuticals, Sierra Oncology LLC
The dynamics of the iron deficiency anemia market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. So far, anemia, in general, is the main indication around which research has been going therefore, iron deficiency anemia still remains an untapped area. At present, only a few pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with iron deficiency anemia.
DelveInsight’s Iron Deficiency Anemia Market Insights report includes a comprehensive understanding of current treatment practices, iron deficiency anemia emerging drugs, market share of individual therapies, and current and forecasted iron deficiency anemia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Iron Deficiency Anemia Market Report
- As per DelveInsight’s analysis, the iron deficiency anemia market size is anticipated to grow at a significant CAGR by 2032 in the 7MM.
- As per DelveInsight estimates, in 2021, the total prevalent population of iron deficiency anemia in the 7MM in 2021 was 31 million cases.
- Globally, leading iron deficiency anemia companies such as Pharmacosmos A/S, AMAG Pharmaceuticals, Inc., Shield Therapeutics, Akebia Therapeutics, Keros Therapeutics, Inc., Keryx Biopharmaceuticals, Rockwell Medical Technologies, Inc., RDC Clinical Pty Ltd, Sierra Oncology LLC, and others are developing novel iron deficiency anemia drugs that can be available in the iron deficiency anemia market in the coming years.
- Some of the key therapies for iron deficiency anemia treatment include Ferric Derisomaltose, Ferumoxytol, Ferric Maltol, Ferric Citrate 1 GM Oral Tablet [AURYXIA], and others.
Discover which therapies are expected to grab the major iron deficiency anemia market share @ Iron Deficiency Anemia Market Report
Iron Deficiency Anemia Overview
Iron deficiency anemia stands as the most widespread type of anemia across the globe, accounting for approximately half of all anemia cases. In IDA, the body’s iron reserves become depleted, leading to a reduction in the number of RBCs. Iron plays a crucial role in RBC production, which is essential for oxygen storage and transport throughout the body. When there’s a shortage of RBCs, organs and tissues receive less oxygen than they require. Iron deficiency anemia symptoms can vary in severity and differ from person to person, often encompassing features such as paleness, fatigue, decreased body temperature, brittle nails, shortness of breath, and more. The iron deficiency anemia diagnosis relies on a physical examination and a blood test, specifically a CBC, which provides information about hemoglobin levels and the number of red blood cells, along with measurements of iron within the patient’s bloodstream. Supplementary diagnostic methods encompass biopsy, upper or lower endoscopy, and additional blood tests assessing iron levels, total iron-binding capacity, and transferrin concentrations.
Iron Deficiency Anemia Epidemiology Segmentation
The iron deficiency anemia epidemiology section provides insights into the historical and current iron deficiency anemia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The iron deficiency anemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Iron Deficiency Anemia Prevalent Cases
- Total Iron Deficiency Anemia Diagnosed Cases
- Total Iron Deficiency Anemia Cases by Gender
- Total Iron Deficiency Anemia Cases by Age
- Iron Deficiency Anemia Severity-Specific Cases
- Total Iron Deficiency Anemia Treated Cases
Download the report to understand which factors are driving iron deficiency anemia epidemiology trends @ Iron Deficiency Anemia Epidemiological Insights
Iron Deficiency Anemia Treatment Market
The treatment approach for iron deficiency anemia is contingent upon its cause and severity. Available treatments encompass the use of iron supplements, medical procedures, surgical intervention, and dietary modifications. In cases of severe iron deficiency anemia, intravenous (IV) iron therapy or blood transfusions may be necessary. The primary objectives of iron deficiency anemia treatment are to address the underlying cause and reinstate normal levels of red blood cells, hemoglobin, and iron.
In November 2000, the US Food and Drug Administration (FDA) granted approval for Venofer (Ferric Oxyhydroxide: Vifor Pharma/American Regent) for the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis while concurrently receiving supplemental erythropoietin therapy. Venofer, also known as iron sucrose (iron (III)-hydroxide sucrose complex), serves as a low-dose intravenous (IV) iron sucrose product utilized for IV therapy in cases where oral iron preparations prove ineffective or are contraindicated, such as in anemic dialysis patients. Outside of the United States, a generic version of this medication is available.
In November 2017, Auryxia (also known as Riona or KRX-0502), developed by Akebia Therapeutics, received approval from the US FDA for the treatment of iron deficiency anemia (IDA) in adults with chronic kidney disease (CKD) who are not undergoing dialysis. Auryxia is an iron-based, noncalcium, and nonchewable compound distinguished by its unique chemical properties, with the active ingredient being ferric citrate.
Learn more about the FDA-approved drugs for iron deficiency anemia @ Drugs for Iron Deficiency Anemia Treatment
Key Iron Deficiency Anemia Therapies and Companies
- Ferric Derisomaltose: Pharmacosmos A/S
- Ferumoxytol: AMAG Pharmaceuticals, Inc.
- Ferric Maltol: Shield Therapeutics
- Ferric Citrate 1 GM Oral Tablet [AURYXIA]: Akebia Therapeutics
To know more about iron deficiency anemia clinical trials, visit @ Iron Deficiency Anemia Treatment Drugs
Iron Deficiency Anemia Market Dynamics
The dynamics of the iron deficiency anemia market are expected to change in the coming years. The iron deficiency anemia market thrives on high sales volumes, offering abundant prospects for drugs to expand their indications. This broader labeling opens up substantial windows of opportunity for these medications. Presently, oral iron products suffer from multiple shortcomings, leaving ample room for innovation. There exists a significant unmet demand for an oral medication that boasts reduced gastrointestinal side effects, improved absorption, enhanced efficacy, less frequent dosing requirements, and superior tolerability.
Furthermore, many potential therapies are being investigated for the treatment of iron deficiency anemia, and it is safe to predict that the treatment space will significantly impact the iron deficiency anemia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the iron deficiency anemia market in the 7MM.
However, several factors are impeding the growth of the iron deficiency anemia market. Limited knowledge and misconceptions can pose challenges in ensuring patients effectively adhere to drug regimens. When patients are on oral therapies, it’s crucial to exercise caution regarding concurrent medication or dietary choices, as they may impede iron absorption. Another significant hurdle in the iron deficiency anemia market is the expected surge in generic drug adoption, which is poised to reduce the market's size.
Furthermore, the iron deficiency anemia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the iron deficiency anemia market growth.
| Iron Deficiency Anemia Report Metrics | Details |
| Study Period | 2019–2032 |
| Iron Deficiency Anemia Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Iron Deficiency Anemia Companies | Pharmacosmos A/S, AMAG Pharmaceuticals, Inc., Shield Therapeutics, Akebia Therapeutics, Keros Therapeutics, Inc., Keryx Biopharmaceuticals, Rockwell Medical Technologies, Inc., RDC Clinical Pty Ltd, Sierra Oncology LLC, and others |
| Key Iron Deficiency Anemia Therapies | Ferric Derisomaltose, Ferumoxytol, Ferric Maltol, Ferric Citrate 1 GM Oral Tablet [AURYXIA], and others |
Scope of the Iron Deficiency Anemia Market Report
- Therapeutic Assessment: Iron Deficiency Anemia current marketed and emerging therapies
- Iron Deficiency Anemia Market Dynamics: Attribute Analysis of Emerging Iron Deficiency Anemia Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Iron Deficiency Anemia Market Access and Reimbursement
Discover more about iron deficiency anemia drugs in development @ Iron Deficiency Anemia Clinical Trials
Table of Contents
| 1. | Iron Deficiency Anemia Market Key Insights |
| 2. | Iron Deficiency Anemia Market Report Introduction |
| 3. | Iron Deficiency Anemia Market Overview at a Glance |
| 4. | Iron Deficiency Anemia Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Iron Deficiency Anemia Treatment and Management |
| 7. | Iron Deficiency Anemia Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Iron Deficiency Anemia Marketed Drugs |
| 10. | Iron Deficiency Anemia Emerging Drugs |
| 11. | Seven Major Iron Deficiency Anemia Market Analysis |
| 12. | Iron Deficiency Anemia Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Iron Deficiency Anemia Epidemiology Forecast
Iron Deficiency Anemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted iron deficiency anemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Iron Deficiency Anemia Pipeline
Iron Deficiency Anemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key iron deficiency anemia companies, including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, among others.
Anemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia companies, including Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, among others.
Anemia in Elderly Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in elderly companies, including AMAG Pharmaceuticals, Rockwell Medical., Keryx Biopharmaceuticals Inc., Sanofi-Aventis U.S. LLC., Shield Therapeutics plc., Pharmacosmos A/S, American Regent, Vifor, Amgen Inc., Japan Tobacco, FibroGen, AstraZeneca, GlaxoSmithKline, Akebia Therapeutics, BioAge Labs Inc., Nemysis, MegaPro Biomedical, Bayer, among others.
Anemia in Chronic Kidney Disease Market
Anemia in Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, among others.
Aplastic Anemia Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aplastic anemia companies, including Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
